HomeORMP • NASDAQ
Oramed Pharmaceuticals, Inc.
$2.38
Jan 13, 9:36:56 AM GMT-5 · USD · NASDAQ · Disclaimer
StockUS listed security
Previous close
$2.39
Day range
$2.38 - $2.38
Year range
$2.00 - $3.67
Market cap
95.94M USD
Avg Volume
198.00K
P/E ratio
23.83
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD)Sep 2024Y/Y change
Revenue
Operating expense
3.09M6.77%
Net income
-19.62M-508.91%
Net profit margin
Earnings per share
-0.48-500.00%
EBITDA
-3.04M-6.97%
Effective tax rate
-6.12%
Total assets
Total liabilities
(USD)Sep 2024Y/Y change
Cash and short-term investments
142.30M-18.70%
Total assets
165.08M-28.50%
Total liabilities
9.56M-88.44%
Total equity
155.52M
Shares outstanding
40.31M
Price to book
0.61
Return on assets
-4.42%
Return on capital
-4.64%
Net change in cash
(USD)Sep 2024Y/Y change
Net income
-19.62M-508.91%
Cash from operations
-7.10M-923.20%
Cash from investing
-34.26M54.39%
Cash from financing
-1.29M-101.73%
Net change in cash
-42.65M-3,183.22%
Free cash flow
-277.62K40.85%
About
Oramed Pharmaceuticals Inc., is a publicly traded company engaged in the development of oral drug delivery systems – most notably an oral insulin capsule for treating type 2 diabetes. The company was founded in 2006 and is headquartered in Jerusalem. Its shares are listed on the NASDAQ Capital Market and the Tel Aviv Stock Exchange. Wikipedia
Founded
2006
Website
Employees
15
Search
Clear search
Close search
Google apps
Main menu